drugset / Trial / NCT02502669

Finasteride Treatment of Severe Nodulocystic Acne

NCT02502669

Phase 2 Completed 106 enrolled Elorac, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of once weekly, high dose oral finasteride compared to placebo for the treatment of severe nodulocystic acne in male subjects.

Timeline

Start
2015-07
Primary completion
2017-06-06
Completion
2017-06-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Finasteride Small molecule 23.5 mg Oral
Comparator Finasteride Small molecule 33.5 mg Oral

Indications